JP7482495B2 - グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 - Google Patents

グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 Download PDF

Info

Publication number
JP7482495B2
JP7482495B2 JP2018564338A JP2018564338A JP7482495B2 JP 7482495 B2 JP7482495 B2 JP 7482495B2 JP 2018564338 A JP2018564338 A JP 2018564338A JP 2018564338 A JP2018564338 A JP 2018564338A JP 7482495 B2 JP7482495 B2 JP 7482495B2
Authority
JP
Japan
Prior art keywords
compound
group
aryl
compounds
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518029A (ja
JP2019518029A5 (OSRAM
Inventor
エム ハーゲン トリー
エス ベックマン ジョセフ
アール ベイルビー パメラ
Original Assignee
オレゴン ステイト ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ステイト ユニバーシティー filed Critical オレゴン ステイト ユニバーシティー
Publication of JP2019518029A publication Critical patent/JP2019518029A/ja
Publication of JP2019518029A5 publication Critical patent/JP2019518029A5/ja
Priority to JP2022100428A priority Critical patent/JP2022137094A/ja
Application granted granted Critical
Publication of JP7482495B2 publication Critical patent/JP7482495B2/ja
Priority to JP2024108985A priority patent/JP2024150504A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018564338A 2016-06-09 2017-06-07 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 Active JP7482495B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022100428A JP2022137094A (ja) 2016-06-09 2022-06-22 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
JP2024108985A JP2024150504A (ja) 2016-06-09 2024-07-05 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348030P 2016-06-09 2016-06-09
US62/348,030 2016-06-09
PCT/US2017/036393 WO2017214297A1 (en) 2016-06-09 2017-06-07 Compounds for delivering glutathione to a target and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100428A Division JP2022137094A (ja) 2016-06-09 2022-06-22 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法

Publications (3)

Publication Number Publication Date
JP2019518029A JP2019518029A (ja) 2019-06-27
JP2019518029A5 JP2019518029A5 (OSRAM) 2020-07-16
JP7482495B2 true JP7482495B2 (ja) 2024-05-14

Family

ID=60578926

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018564338A Active JP7482495B2 (ja) 2016-06-09 2017-06-07 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
JP2022100428A Pending JP2022137094A (ja) 2016-06-09 2022-06-22 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
JP2024108985A Pending JP2024150504A (ja) 2016-06-09 2024-07-05 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022100428A Pending JP2022137094A (ja) 2016-06-09 2022-06-22 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
JP2024108985A Pending JP2024150504A (ja) 2016-06-09 2024-07-05 グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法

Country Status (7)

Country Link
US (2) US20190106456A1 (OSRAM)
EP (1) EP3468563B1 (OSRAM)
JP (3) JP7482495B2 (OSRAM)
AU (1) AU2017277532B2 (OSRAM)
CA (1) CA3025665A1 (OSRAM)
IL (1) IL263469B (OSRAM)
WO (1) WO2017214297A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456825B (zh) * 2021-06-17 2023-07-11 温州医科大学 一种线粒体靶向的谷胱甘肽衍生物纳米制剂及应用
CN113480595B (zh) * 2021-06-17 2023-07-11 温州医科大学 一种线粒体靶向谷胱甘肽衍生物、制备方法及应用
WO2024172390A1 (ko) * 2023-02-13 2024-08-22 가톨릭대학교 산학협력단 신규한 미토콘드리아 표적화 화합물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US20070099845A1 (en) 2003-11-25 2007-05-03 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US20080220093A1 (en) 1998-11-23 2008-09-11 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
WO2013177293A1 (en) 2012-05-22 2013-11-28 Biogen Idec Ma Inc. Trapping reagents for reactive metabolites screening
US20160129070A1 (en) 2014-11-10 2016-05-12 South Dakota Board Of Regents Glutathione Disulfide Compositions and Related Methods for the Treatment of Cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747009B2 (en) * 2002-09-19 2004-06-08 Universiteit Leiden Peptidomimetic glutathione analogs
EP2398500B1 (en) * 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US20080220093A1 (en) 1998-11-23 2008-09-11 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20070099845A1 (en) 2003-11-25 2007-05-03 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
WO2013177293A1 (en) 2012-05-22 2013-11-28 Biogen Idec Ma Inc. Trapping reagents for reactive metabolites screening
US20160129070A1 (en) 2014-11-10 2016-05-12 South Dakota Board Of Regents Glutathione Disulfide Compositions and Related Methods for the Treatment of Cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ＡＣＳ Ｃｈｅｍｉｃａｌ Ｂｉｏｌｏｇｙ，２０１０年，Ｖｏｌ．５， Ｎｏ．４，ｐ．４０５－４１４
Ｂｉｏｃｈｉｍｉｃａ ｅｔ Ｂｉｏｐｈｙｓｉｃａ Ａｃｔａ，Ｖｏｌ．１７６２，２００６年，ｐ．２５６－２６５
Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ，１９９０年，Ｖｏｌ．３３， Ｎｏ．３，ｐ．１００９－１０１４
Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ，１９９８年，Ｖｏｌ．４１， Ｎｏ．４，ｐ．５１５－５２９
Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ，２０１３年，Ｖｏｌ．１３５，ｐ．７６９３－７７０４
Ｍｏｌｅｃｕｌｅｓ，２０１０年，Ｖｏｌ．１５，ｐ．１２４２－１２６４
Ｔｈｅ Ａｎｎｕａｌ Ｒｅｖｉｅｗ ｏｆ Ｐｈａｒｍａｃｏｌｏｇｙ ａｎｄ Ｔｏｘｉｃｏｌｏｇｙ，２００７年，Ｖｏｌ．４７，ｐ．６２９－６５６

Also Published As

Publication number Publication date
EP3468563B1 (en) 2023-09-13
AU2017277532A1 (en) 2018-12-20
EP3468563A1 (en) 2019-04-17
CA3025665A1 (en) 2017-12-14
IL263469A (en) 2019-01-31
JP2019518029A (ja) 2019-06-27
WO2017214297A1 (en) 2017-12-14
JP2022137094A (ja) 2022-09-21
US20250282817A1 (en) 2025-09-11
AU2017277532B2 (en) 2022-09-15
IL263469B (en) 2022-08-01
EP3468563A4 (en) 2020-07-29
JP2024150504A (ja) 2024-10-23
US20190106456A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
JP2024150504A (ja) グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
CN110177788B (zh) 作为bcl-2选择性凋亡诱导剂的化合物
JP2022119990A (ja) アポトーシス誘発剤
CN108395443B (zh) 抑制程序性死亡受体配体1的环状化合物及其用途
IL321703A (en) Pyrrolidine compounds
AU9288998A (en) New npy antagonists
US11555013B2 (en) Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
AU2020234859A1 (en) Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor
JP2023525748A (ja) Ｂｃｌ－２阻害剤としての化合物
CN112105601B (zh) 作为细胞死亡抑制剂的苯磺酰胺衍生物和相关的ferrostatin-1类似物
US11834424B2 (en) Compounds useful as chaperone-mediated autophagy modulators
WO2022173805A1 (en) Amide and ether substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereof
US20110136840A1 (en) Anti-infective agents
JP2020505388A (ja) カスパーゼ阻害薬としての二環式化合物
JP4728640B2 (ja) ニューロトロフィン関連疾患の治療用医薬組成物
WO2017175185A1 (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
US10188659B2 (en) IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
JP4986335B2 (ja) Ｖｄａｃ機能阻害剤
US11679103B2 (en) Multi-targeting agents for Alzheimer's disease therapy
WO2011073492A1 (es) Derivados de aminociclitoles, procedimiento de obtención y usos
US20240254098A1 (en) Thioester prodrugs for the treatment of renal anomalies
WO2018234232A1 (en) Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
WO2021163631A1 (en) Calpain-2 inhibitor compounds and methods of treatment
WO2024226581A1 (en) Antiviral 1,3-di-oxo-indene compounds
CN116283664A (zh) 一种硝基儿茶酚衍生物、包含其的药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220622

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220623

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220714

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220802

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220809

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220930

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240422

R150 Certificate of patent or registration of utility model

Ref document number: 7482495

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150